LY 3114062

Drug Profile

LY 3114062

Alternative Names: LY-3114062

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Antibodies; Antirheumatics
  • Mechanism of Action Interleukin 17 modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Arthritis

Most Recent Events

  • 01 Jun 2014 Phase-I clinical trials in Arthritis in Bulgaria and Moldova (IV)
  • 01 Jun 2014 Phase-I clinical trials in Arthritis in Bulgaria and Moldova (SC)
  • 19 May 2014 Preclinical trials in Arthritis in USA (IV & SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top